Zobrazeno 1 - 8
of 8
pro vyhledávání: '"William J. Hrushesky"'
Autor:
Charles L. Bennett, Nancy Olivieri, Shamia Hoque, David Aboulafia, Anne Ventrone, Courtney Lubaczewski, Betty Dong, Benjamin Schooley, Bartlett J. Witherspoon, Paul S. Ray, William J. Hrushesky, John Restaino, Henrik S. Thomsen, Dennis Mangano, Christina Mora-Mangano, June M. McKoy, Martin Schoen, Kevin Knopf, Linda Martin, Steven Rosen
Publikováno v:
The Journal of Scientific Practice and Integrity (2022)
# Background We previously described experiences of clinicians who published adverse drug reaction reports. We now report on threats and intimidations leveled against clinicians and scientists who received publicly documented threats after communica
Externí odkaz:
https://doaj.org/article/c58a1f473a3e44cfa3fb8a9e0941656a
Autor:
Charles L. Bennett, Shamia Hoque, Nancy Olivieri, Matthew A. Taylor, David Aboulafia, Courtney Lubaczewski, Andrew C. Bennett, Jay Vemula, Benjamin Schooley, Bartlett J. Witherspoon, Ashley C Godwin, Paul S. Ray, Paul R. Yarnold, Henry C. Ausdenmoore, Marc Fishman, Georgne Herring, Anne Ventrone, Juan Aldaco, William J. Hrushesky, John Restaino, Henrik S. Thomsen, Robert Marx, Cesar Migliorati, Salvatore Ruggiero, Chadi Nabhan, Kenneth R. Carson, June M. McKoy, Y. Tony Yang, Martin W. Schoen, Kevin Knopf, Linda Martin, Oliver Sartor, Steven Rosen, William K. Smith
Publikováno v:
EClinicalMedicine, Vol 31, Iss , Pp 100693- (2021)
Background: Adverse drug/device reactions (ADRs) can result in severe patient harm. We define very serious ADRs as being associated with severe toxicity, as measured on the Common Toxicity Criteria Adverse Events (CTCAE)) scale, following use of drug
Externí odkaz:
https://doaj.org/article/7660e72814e34fe8aaa2b0680f081e61
Autor:
Peter Webster, Georg A. Bjarnason, William J. Hrushesky, Michael K. Wong M.D., Izabella Morava-Protzner, Mark Towers
Publikováno v:
Cancer. 75:2558-2564
Background. Continuous infusion of 2'-deoxy-5-fluorouridine (FUdR) has shown promise in its activity against metastatic renal cell carcinoma. Its side-effect profile is dominated by gastrointestinal toxicity ; there are no known adverse pulmonary rea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83ab3a1ae784e277627e6e63b332c4a9
https://doi.org/10.1002/1097-0142(19950515)75:10<2558::aid-cncr2820751024>3.0.co
https://doi.org/10.1002/1097-0142(19950515)75:10<2558::aid-cncr2820751024>3.0.co
Autor:
William J. Hrushesky
It is proposed to use this breast cancer of C(3)H mice to determine whether or not hormone dependent immunocyte suppression is, in part, responsible for the mammalian fertility cycle modulation of the capacity of the cancer to spread after attempted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f86db7444952856aefbb701137343324
https://doi.org/10.21236/ada415581
https://doi.org/10.21236/ada415581
Publikováno v:
Medical and Pediatric Oncology. 2:441-442
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcc7bdd726f4412c55785f7df65dbbe7
https://doi.org/10.1002/mpo.2950020411
https://doi.org/10.1002/mpo.2950020411
Autor:
William J. Hrushesky
Publikováno v:
JAMA: The Journal of the American Medical Association. 236:138
To the Editor.— A 56-year-old black man with stage D carcinoma of the prostate was treated with weekly fluorouracil doses of 750 mg/sq m for 24 consecutive weeks. The total dose of fluorouracil received was 27 gm. A good partial remission was attai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eff68b43da65f5ea22527a5af48d2d6c
https://doi.org/10.1001/jama.1976.03270020012002
https://doi.org/10.1001/jama.1976.03270020012002
Autor:
Shamia Hoque, Brian J Chen, Martin W Schoen, Kenneth R Carson, Jesse Keller, Bartlett J Witherspoon, Kevin B Knopf, Y Tony Yang, Benjamin Schooley, Chadi Nabhan, Oliver Sartor, Paul R Yarnold, Paul Ray, Laura Bobolts, William J Hrushesky, Michael Dickson, Charles L Bennett
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0234541 (2020)
Erythropoisis stimulating agent (ESA) use was addressed in Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) meetings between 2004 and 2008. FDA safety-focused regulatory actions occurred in 2007 and 2008. In 2007, black box
Externí odkaz:
https://doaj.org/article/db22cc567bfb42b08476116e945c2620
Autor:
Charles L Bennett, Benjamin Schooley, Matthew A Taylor, Bartlett J Witherspoon, Ashley Godwin, Jayanth Vemula, Henry C Ausdenmoore, Oliver Sartor, Y Tony Yang, James O Armitage, William J Hrushesky, John Restaino, Henrik S Thomsen, Paul R Yarnold, Terence Young, Kevin B Knopf, Brian Chen
Publikováno v:
PLoS ONE, Vol 14, Iss 7, p e0219521 (2019)
Oncology-associated adverse drug/device reactions can be fatal. Some clinicians who treat single patients with severe oncology-associated toxicities have researched case series and published this information. We investigated motivations and experienc
Externí odkaz:
https://doaj.org/article/cd483feedc194083bb6e684e36fe4e63